Pegylated interferon α/ribavirin therapy enhances bone mineral density in children with chronic genotype 4 HCV infection

Megahed, Ahmed; Salem, Nanees; Fathy, Abeer; Barakat, Tarik; Alsayed, Mona Abd El Latif; Abdelmabood, Suzy; Zalata, Khaled; Abdalla, Ahmed

doi:10.1007/s12519-017-0013-x

Cited by 4 publications

(4 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…82 Overall, there have been eleven clinical trials (1 randomized and 10 open-label) on the use of pegylated interferon (PEG IFN) in adolescents and children less than 12 years. [92][93][94][95][96][97][98][99][100][101][102] In genotype 1, the SVR of PEG IFN and ribavirin was suboptimal compared to DAA, with an SVR of only 52% in those with HCV genotype 1 and 4, but 89% in genotypes 2 and 3. 82,103 PEG IFN and ribavirin are associated with significant side effects during treatment, and potentially irreversible after-therapy side effects, such as thyroid disease, type 1 diabetes, ophthalmological complications and growth impairment.…”

Section: Antiviral Treatment and Indications For Treatmentmentioning

confidence: 99%

“…82,103 PEG IFN and ribavirin are associated with significant side effects during treatment, and potentially irreversible after-therapy side effects, such as thyroid disease, type 1 diabetes, ophthalmological complications and growth impairment. [92][93][94][95][96][97][98][99][100][101][102] In clinical practice, IFN treatment has been mainly limited to the few children with persistently elevated serum aminotransferases, progressive liver disease (i.e. fibrosis on liver histology) or HIV coinfection, 104 while for most children, follow up without treatment until adulthood has been preferred.…”

Section: Antiviral Treatment and Indications For Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis C virus infection in children and adolescents

Indolfi

Easterbrook

Dusheiko

et al. 2019

The Lancet Gastroenterology & Hepatology

151

147

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and associated morbidity and mortality worldwide. Short-course, oral, curative, direct-acting antiviral regimens have now transformed treatment for HCV infection. Since the launch in 2016 of the first global strategy towards elimination of viral hepatitis as a public health threat by 2030, the predominant focus of the global response has been on treatment of adults, who bear the greatest burden of morbidity and mortality of HCV related chronic liver disease. There has been much less attention paid to addressing response to HCV in children and adolescents, in part because of the lack of data to inform specific paediatric management practices and policy. In this review, we summarize current knowledge on epidemiology, natural history, and treatment of chronic HCV infection in adolescents and children, and highlight key differences from infection acquired in adulthood. The estimated global prevalence and burden in children aged 1 to 19 years is 0•15% and 3•5 (3•1-3•9) million, respectively. HCV infection is usually asymptomatic during childhood, and cirrhosis and hepatocellular carcinoma are rare. Sofosbuvir, ledipasvir and ribavirin have now received regulatory approval and guidelines recommend their use in adolescents ages >12 years with HCV infection. Key actions to address the current policy gaps and achieve treatment scale-up comparable to that in adults include: establishment of a testing and treatment access campaign targeted at children and adolescents; fast-track evaluation of pangenotypic regimens and accelerated approval of paediatric formulations. Research gaps that need to be addressed include age-specific seroprevalence studies of HCV viraemia in priority countries; further validation of non-invasive tests in children; and establishment of paediatric treatment registries and international consortia to promote collaborative research agenda.

show abstract

Section: Antiviral Treatment and Indications For Treatmentmentioning

confidence: 99%

Section: Antiviral Treatment and Indications For Treatmentmentioning

confidence: 99%

Hepatitis C virus infection in children and adolescents

Indolfi

Easterbrook

Dusheiko

et al. 2019

The Lancet Gastroenterology & Hepatology

151

147

View full text Add to dashboard Cite

show abstract

“…The schematic of study selection process is provided in Figure 1, whereas the complete results of the searches are described in the Appendixes 2 to 5 (Supplemental Digital Content, http:// links.lww.com/MPG/B238). Overall, 16 studies met the inclusion criteria (35)(36)(37)(38)(44)(45)(46)(47)(48)(49)(50)(51)(52)(53)(54)(55). The inter-rater reliability for study inclusion was high (f ¼ 1).…”

Section: Resultsmentioning

confidence: 99%

Treatment of Chronic Hepatitis C Virus Infection in Children

Indolfi

Hierro

Dezsőfi

et al. 2018

J. pediatr. gastroenterol. nutr.

105

View full text Add to dashboard Cite

show abstract

“…Studies have included usually samples of less than 50 patients treated with peginterferon plus ribavirin regimens. Although limitations of these studies are evident, they have demonstrated that BMD values at the lumbar spine and the femoral neck improve after the treatment[ 146 , 147 ], but controversial data have been also reported[ 148 ].…”

Section: Effects Of Svrmentioning

confidence: 99%

Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response

Cuesta¹,

Márquez-Coello²,

Illanes-Álvarez³

et al. 2022

WJH

View full text Add to dashboard Cite

Loss of follow-up or reinfections hinder the expectations of hepatitis C eradication despite the existence of highly effective treatments. Moreover, the elimination of the infection does not imply the reversion of those chronic alterations derived from the previous infection by hepatitis C virus (HCV). This review analyzes the risk factors associated with loss to follow-up in diagnosis or treatment, and the possibility of reinfection. Likewise, it assesses the residual alterations induced by chronic HCV infection considering the liver alterations (inflammation, fibrosis, risk of decompensation, hepatocellular carcinoma, liver transplantation) and, on the other hand, the comorbidities and extrahepatic manifestations (cryoglobulinemia, non-Hodgkin lymphoma, peripheral insulin resistance, and lipid, bone and cognitive alterations). Peculiarities present in subjects coinfected with human immunodeficiency virus are analyzed in each section.

show abstract

Pegylated interferon α/ribavirin therapy enhances bone mineral density in children with chronic genotype 4 HCV infection

Abstract: Low BMD is detectable in a proportion of CHC children. Antiviral therapy leads to a sustainable increase in BMD.

Cited by 4 publications

References 44 publications

Hepatitis C virus infection in children and adolescents

Hepatitis C virus infection in children and adolescents

Treatment of Chronic Hepatitis C Virus Infection in Children

Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response

Contact Info

Product

Resources

About